Cencora stock trades at EUR 302.00 ahead of quarterly results

Published on 10/19/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora stock costs EUR 302.00 on October 19, 2026 before its November 4 results. Baird raised its target to USD 373.00 on October 12, 2026.

Business figures and scheduled dates

Baird raised its Cencora target to USD 373.00 on October 12, 2026.
Fiscal third-quarter revenue reached USD 84.8 billion, up 5.00 percent year over year.
Cencora stock traded at EUR 302.00 at 10:09 a.m. CEST at Lang & Schwarz on October 19, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) traded at EUR 302.00 at Lang & Schwarz on October 19, 2026 at 10:09 a.m. CEST, with the next fiscal results scheduled for November 4. MarketBeat reported that Robert W. Baird raised its price target from USD 370.00 to USD 373.00 on October 12, 2026. The target update gives the stock a fresh valuation reference ahead of the company report.

Quarterly figures set the baseline

Cencora's fiscal third-quarter revenue reached USD 84.8 billion for the period ended June 30, 2026, up 5.00 percent from the prior-year quarter. The earnings-call transcript carried by Yahoo Finance said adjusted earnings per share guidance for fiscal 2026 rose to USD 17.75-17.95 from USD 17.70-17.90. The same transcript put U.S. Healthcare Solutions revenue at USD 74.9 billion, an increase of 5.00 percent.

The guidance change matters because Cencora operates with high distribution volumes and narrow margins. Revenue growth remains the larger scale indicator, while the adjusted earnings range captures management's view of operating leverage through the end of fiscal 2026.

Three dated signals for Cencora

On August 5, 2026, Cencora reported fiscal third-quarter revenue of USD 84.75 billion and adjusted earnings per share of USD 4.48, according to MarketBeat. On October 2, 2026, Cencora announced that its fiscal fourth-quarter results would be released on November 4, 2026, before trading on the New York Stock Exchange, according to Cencora. On October 12, 2026, Baird lifted its target to USD 373.00.

What does the target mean?

Baird's USD 373.00 target sits alongside a fiscal 2026 adjusted earnings outlook of USD 17.75-17.95. The company is listed on the New York Stock Exchange under COR, and its healthcare distribution business serves manufacturers, providers, and health systems across more than 50 countries, according to ProFactorInvest.

November results are the next date

Cencora's next scheduled reporting date is November 4, 2026, before the New York Stock Exchange opens, followed by an earnings call at 8:30 a.m. ET, according to the company's release. That appointment will test whether the fiscal 2026 guidance range remains appropriate after the third-quarter revenue increase.

Stock price before the report

The euro quotation places Cencora stock at EUR 302.00 in regular Xetra-session trading hours, based on the Lang & Schwarz timestamp of October 19, 2026 at 10:09 a.m. CEST. The upcoming report and the USD 373.00 Baird target give investors two dated reference points for assessing the next company update. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.